ABUS Arbutus Biopharma Corporation
Health Care, filed as ARBUTUS BIOPHARMA CORP (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab
- 1 exit
In 2026 Q2 David Witzke sold out of Arbutus Biopharma.
Who owns ABUS
Sorted by value, long equity only, as of 2026 Q2. Exits show their last held size.
| History | |||||
|---|---|---|---|---|---|
| David Witzke, Avidity Partners Management exited 2026 Q2 Last 2026 Q1 | Exit −0.12% | 125,000 | $525K | History |
Insider trades
Open-market buys and sales by ABUS's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- None no planned (10b5-1) sales
No open-market buys or sales on file.
Also filed in the last 12 months, not counted as buying or selling: 8 option exercises, 5 sales back to the company, 4 share withholdings for taxes, and 2 stock grants.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 1.02,5.02,8.01,9.01 | Filing Doc | |
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13D/A | — | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| SCHEDULE 13D/A | — | Filing Doc | |
| 10-K | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 1.01,8.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc |
No filings match this filter.
Financials
US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.
Income statement
Balance sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total current assets | $132.03M | $127.32M | $94.46M |
| Total non-current assets * | $12.37M | $4.39M | $0.162M |
| Total assets | $144.4M | $131.71M | $94.62M |
| Total current liabilities | $22.49M | $15.62M | $6.01M |
| Total non-current liabilities * | $15.9M | $18.72M | $12.04M |
| Total equity | $106.02M | $97.37M | $76.58M |
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon